NCT00639626View on ClinicalTrials.gov

Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Cystic Fibrosis Related Diabetes

Interventions

DRUG

insulin detemir [rDNA origin] injection

Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Nationwide Children's Hospital

OTHER